When a paper comes out that demonstrates an FTO inhibitor or knockdown model synergises with an anti-CD47 drug, then I will add it to the table.
An anti-CD47 drug like Magrolimab, which was bought for USD $4.9B by Gilead, is one of the many drugs that are yet to have been tested for synergies with an FTO inhibitor in the lab. Some of the other massive earning drugs include BTK inhibitors, CDK 4/6 inhibitors, anti-CD34 inhibitors, and HER-2 monoclonals.
If anyone thinks the FTO opportunity is limited to the data I have found, they are wrong. The limitation is that all the possibilities have not been fully investigated yet.
Speculative M&A Transaction Analysis, page-575
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.010(0.64%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.62 | $1.57 | $163.1K | 102.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 900 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 1421 | 2 |
View Market Depth
| Last trade - 13.51pm 16/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |